Full Breakdown
Marty Makary Resigns as FDA Commissioner Amid Leadership Turmoil
5/14/2026, 12:42:44 AM
Core Event
On 12 May 2026, FDA Commissioner Dr. Marty Makary announced his resignation after 13 months in office. Deputy Commissioner for Food Kyle Diamantas was named acting commissioner, leaving the agency without a Senate-confirmed leader while other HHS posts remain vacant.
Background & Context
Health Secretary Robert F. Kennedy Jr.’s “Make America Healthy Again” agenda has reshaped HHS priorities toward diet, lifestyle and affordability. The department has operated with multiple acting officials—no confirmed surgeon-general, an acting CDC director, and a NIH director temporarily overseeing the CDC—fueling concerns about scientific oversight.
Key Figures & Groups
- Marty Makary – former FDA commissioner, surgeon-researcher.
- Kyle Diamantas – deputy commissioner for foods, former corporate lawyer, now acting FDA head.
- Donald Trump – President, publicly praised Makary but declined detailed comment.
- Robert F. Kennedy Jr. – HHS secretary, central to leadership decisions.
- Dr. Daniel Jernigan – former senior CDC employee, critic of department management.
- Dr. Peter Lurie – former FDA official, Center for Science in the Public Interest.
- Marjorie Dannenfelser – president, SBA Pro-Life America (anti-abortion group).
- Bill Cassidy – Senate HELP Committee chair (R-LA).
Timeline
- 25 Mar 2025 – Makary confirmed as FDA commissioner.
- Mar 2025 – HHS initiates layoffs affecting ? 3,500 FDA staff.
- Feb 2026 – FDA rejects Moderna mRNA flu-vaccine; later reverses after White House pressure.
- 12 May 2026 – Makary resigns; Trump announces Diamantas as acting head.
- Mid-2026 – Senate expected to consider permanent FDA nominee; Makary’s scheduled budget testimony postponed.
Data & Statistics
- No Senate-confirmed surgeon-general; CDC led by acting director.
- ? 3,500 FDA employees laid off in 2025.
- Two senior FDA officials (George Tidmarsh, Richard Pazdur) resigned in 2025-26.
- Vinay Prasad left the agency twice within a year.
- Makary’s tenure saw ? 50 policy initiatives, many pending rulemaking.
Why It Matters / Impact
The leadership gap threatens regulatory predictability for drugs, vaccines and food safety, potentially delaying approvals and eroding public trust ahead of the 2026 midterm elections. Industry groups warn of market volatility, while critics argue the vacancy hampers evidence-based health policy.
Official Statements & Responses
The White House noted Makary “was having some difficulty” but offered no further detail. President Trump called him “a great guy” and said the deputy would “take over temporarily.” HHS officials asserted that CDC functions remain “intact and effective” and framed recent changes as efforts to restore “gold-standard science and accountability.”
Criticism & Opposition
Anti-abortion advocates, led by SBA Pro-Life America, demanded Makary’s removal for allegedly delaying a safety review of mifepristone. Pro-vape industry representatives criticized his resistance to fruit-flavored e-cigarettes. Republican lawmakers, including Bill Cassidy and Darin LaHood, condemned perceived “mismanagement” and “endless chaos” at the FDA.
Conflicting Reports & Gaps
Sources differ on whether Makary resigned voluntarily or was fired. Trump claimed ignorance of the decision, while a senior administration official said HHS Secretary Kennedy made the call. Reported motives range from the vape dispute to anti-abortion pressure and broader agency dysfunction, with no definitive attribution.
Verbatim Quotes
- “Marty is a great guy. He's a friend of mine. He's a wonderful man, and he's going to be off and the assistant, the deputy, is taking over temporarily,” — Donald Trump, President
- “It's a sign that something is not right in this department,” — Dr. Daniel Jernigan, former senior CDC employee
- “Kyle Diamantas now has a nearly impossible charge,” — Dr. Peter Lurie, former FDA official, CSPI
- “The driver for the secretary is the ideology,” — Dr. Daniel Jernigan
- “Makary must go,” — Marjorie Dannenfelser, SBA Pro-Life America President
- “Dr. President Trump, Please accept my resignation, effective today,” — Marty Makary, resignation letter
What's Next
Kyle Diamantas will steer the FDA pending Senate confirmation of a permanent commissioner. He is slated to testify on the FY 2027 budget, and the agency faces pressure to stabilize drug-review processes while navigating pending initiatives on ultra-processed foods and vaccine policy.
